Not every high-yield dividend stock belongs in a Roth IRA, but these four generate the kind of ordinary income that makes tax-free compounding matter most. One has raised its payout 60 times in 56 years, another locks tenants into leases\u2026<\/p>\n
Roth IRAs let dividends compound tax-free forever, which makes them the ideal wrapper for names that spit out ordinary-income distributions taxed at your marginal rate outside the account. The four below yield well above the S&P 500 average, and each brings a different flavor of durable cash flow: a business development company<\/a>, a gaming net-lease REIT, a tobacco cash machine, and a large-cap pharma. As one reference point, Ares Capital (NASDAQ:ARCC<\/a> | ARCC Price Prediction<\/a>) alone reports $1.92 in annualized dividends per share, a payout policy backed by 17 years of stable or increasing regular quarterly dividends.<\/p>\n Ares Capital: Ultra-High-Yield Anchor in Private Credit<\/p>\n Ares Capital yields 9.76% at a current price of $19.86, with a declared quarterly payout of $0.48 that has held steady from the 2023-03-14 through 2026-09-15 ex-dividend dates.<\/p>\n Safety read. Q2 2026 core EPS of $0.47 comfortably covers the $0.48 dividend, and net investment income rose to $359 million from $342 million a year earlier. The balance sheet carries roughly $6.0 billion of available liquidity with leverage at 1.15x. Because BDC distributions are largely ordinary income, the Roth IRA tax shelter is especially valuable.<\/p>\n Bull case. ARCC runs the largest publicly traded BDC portfolio at $29.35 billion across 619 companies, 71% floating rate, and a weighted average yield on debt of 10.3%. CEO Kort Schnabel described a portfolio \u201csupported by consistent Core Earnings, healthy portfolio performance and historically low levels of non-accruing loans and problem assets.\u201d<\/p>\n Risk. Non-accruals climbed to 2.4% at cost from 1.8%, NAV per share slipped to $19.35 from $19.94 at year-end 2025, and GAAP EPS fell to $0.24 from $0.52 on unrealized portfolio losses. A credit cycle downturn hits BDC book values first.<\/p>\n VICI Properties: Experiential REIT With CPI-Linked Escalators<\/p>\n VICI Properties (NYSE:VICI<\/a>) yields 7.28% at $25.33. The board just bumped the quarterly payout to $0.46 from $0.45 beginning with the 2026-09-17 ex-dividend date, extending a raise pattern that includes prior step-ups to 0.415 in 2024 and 0.39 in 2023.<\/p>\n Safety read. Q2 2026 AFFO per share was $0.62, up 4.6% year over year, and management raised full-year 2026 AFFO guidance to $2.45 to $2.47 per diluted share. Portfolio occupancy sits at 100% with a 39.6-year weighted-average lease term and CPI-linked escalators baked in. VICI distributions are non-qualified ordinary income, which makes Roth placement highly tax-efficient.<\/p>\n Bull case. Revenue grew 5.7% year over year to $1.06 billion in Q2, with tenant count expanded to 16 after closing the $1.16 billion Golden Entertainment acquisition. CEO Edward Pitoniak said \u201cVICI\u2019s partner-driven model will continue to generate attractive, durable growth for our shareholders.\u201d<\/p>\n Risk. Leverage is meaningful at ~$17.2 billion of total debt, and tenant concentration is real: Caesars accounts for roughly 38% of rent and MGM another 32%. Shares are down 18.66% over the past year on rate concerns.<\/p>\n Altria: Tobacco Cash Machine With Decades of Raises<\/p>\n Altria (NYSE:MO<\/a>) yields 6.16% at $70.82, and the board just hiked the quarterly dividend to $1.11 from $1.06 for the 2026-09-15 ex-dividend date. That marked Altria\u2019s 60th dividend increase in the past 56 years.<\/p>\n Safety read. Full-year 2025 dividends paid totaled $7.0 billion, with another $1.8 billion paid in Q1 2026. Adjusted diluted EPS of $1.32 in Q1 easily covered the payout, and management reaffirmed full-year 2026 adjusted diluted EPS guidance of $5.56 to $5.72. The quarterly dividend record extends back to 1999.<\/p>\n Bull case. Smokeable operating income rose 6.3% to $2.68 billion in Q1 at a 65.1% margin. Altria returned $8 billion to shareholders in 2025 through dividends and buybacks. CEO Billy Gifford said, \u201cOur highly cash-generative businesses supported significant returns to shareholders through dividends and share repurchases.\u201d Shares are up 26.77% year to date.<\/p>\n Risk. Domestic cigarette volumes fell 5% in Q1 2026, Marlboro retail share slipped 1.4 points to 39.7%, and the on! nicotine pouch share dropped 4.2 points to 13.4% under Zyn pressure. The company also carries negative shareholders\u2019 equity of -$3.2 billion.<\/p>\n Pfizer: Big Pharma Turnaround With an Elevated Payout<\/p>\n Pfizer (NYSE:PFE<\/a>) yields 6.22% at $27.99, with the quarterly dividend at $0.43. The payout has stepped up from $0.42 to $0.43 since the January 2025 declaration, extending a slow-and-steady increase pattern visible across the 2010 through 2026 record.<\/p>\n Safety read. Q1 2026 revenue of $14.45 billion grew 5.4% year over year, and adjusted diluted EPS of $0.75 beat the $0.72 estimate, the fifth consecutive EPS beat. Pfizer paid $2.4 billion in dividends in Q1 2026, and management is prioritizing the dividend with no buybacks anticipated in 2026. Free cash flow yield is around 5.75%.<\/p>\n Bull case. Launched and acquired products grew 22% operationally, with Padcev up 39% and Nurtec ODT\/Vydura up 41%. The Vyndamax patent settlement extends effective US exclusivity to June 2031. Full-year 2026 guidance calls for revenue of $59.5 billion to $62.5 billion. Shares are up 20.52% over the past year.<\/p>\n Risk. Generic and biosimilar competition will cost roughly $1.5 billion in unfavorable revenue impact in 2026, Comirnaty revenue fell 59% and Paxlovid 63%, and policy overhangs include Most-Favored-Nation pricing, TrumpRx, and the IRA Medicare Part D redesign. Net debt to EBITDA sits at 3.26.<\/p>\n Putting the Four Together<\/p>\n Each of these payouts is currently well covered by earnings or AFFO, and every one gets a tax boost from Roth placement because their distributions run largely as ordinary income outside the wrapper. ARCC delivers the highest yield and the most credit-cycle sensitivity, VICI pairs a growing dividend with 39-plus-year lease terms, Altria brings a six-decade raise record backed by 65%-margin smokeable profits, and Pfizer offers the deepest valuation reset with a forward P\/E of 10. Held together in a Roth IRA, the group compounds an elevated blended yield without the annual tax drag that would erode it in a taxable brokerage account (we sketched a full plan for turning a mid six-figure balance into $1,500 a month of income in a free report here<\/a>).<\/p>\n